文献速递慢性肾脏病

罗沙司他与达依泊汀α对眼科影响的两项3期研究

Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin.
PubMed 文献 · Kidney Int Rep · 2022-01-19

在日本开展的CL-0307和CL-0310两项3期研究,分别纳入透析依赖和非透析依赖的慢性肾脏病贫血患者,随机接受罗沙司他或达依泊汀α治疗,评估至第24周的眼科影像学和视力。结果显示两组新发或加重的视网膜出血比例无显著差异,视网膜厚度、视力等指标也无差异。

要点

  • 透析依赖患者中,罗沙司他组新发或加重视网膜出血比例为32.4%(46/142),达依泊汀α组为36.6%(53/145)。
  • 非透析依赖患者中,罗沙司他组新发或加重视网膜出血比例为31.4%(38/121),达依泊汀α组为39.8%(51/128)。
  • 两组在视网膜厚度、视力、硬性渗出、棉絮斑及视网膜内/下积液方面均无差异。

核心结论

  • 在这两项研究中,与达依泊汀α相比,罗沙司他未增加眼科不良事件风险。

研究设计与样本

  • 在日本开展的CL-0307(NCT02952092)和CL-0310(NCT02988973)两项3期、达依泊汀α对照研究,分别纳入透析依赖和非透析依赖的慢性肾脏病贫血患者,随机接受罗沙司他或达依泊汀α治疗。
  • CL-0307中302例患者(罗沙司他150例,达依泊汀α152例)接受至少一剂研究药物并纳入分析;CL-0310中262例患者(罗沙司他131例,达依泊汀α131例)接受至少一剂研究药物并纳入分析。
  • 眼科影像学和视力评估进行至第24周或研究终止,眼科影像由对治疗分组设盲的独立阅片者集中评估。

主要发现

  • 透析依赖患者中,罗沙司他组和达依泊汀α组新发或加重视网膜出血的比例分别为32.4%(46/142)和36.6%(53/145)。
  • 非透析依赖患者中,罗沙司他组和达依泊汀α组新发或加重视网膜出血的比例分别为31.4%(38/121)和39.8%(51/128)。
  • 亚组分析(基线有/无视网膜出血、基线有/无糖尿病)中呈现相似趋势。
  • 两项研究中,任一时点两组间视网膜厚度、视力、硬性渗出或棉絮斑的存在、视网膜内和视网膜下积液的存在均无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Roxadustat is an orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that represents a novel therapeutic option for patients with anemia of chronic kidney disease (CKD). METHODS: Conducted in Japan, CL-0307 (NCT02952092) and CL-310 (NCT02988973) were phase 3, darbepoetin alfa (DA)-controlled studies conducted in dialysis-dependent (DD) and non-DD (NDD) patients with CKD, respectively, where patients were randomized to receive roxadustat or DA. Ophthalmic imaging and assessments of visual acuity were performed up to week 24 or at study discontinuation. Ophthalmic imaging was centrally evaluated by independent readers masked to the study treatment. RESULTS: In CL-0307, 302 patients (roxadustat, n = 150; DA, n = 152) received ≥1 dose of the study drug and were included in this analysis. In CL-0310, 262 patients (roxadustat, n = 131; DA, n = 131) received ≥1 dose of the study drug and were included in this analysis. Proportions of DD patients with new or worsening retinal hemorrhages (RHs) in the roxadustat group and DA group were 32.4% (46 of 142) and 36.6% (53 of 145), respectively. Proportions of NDD patients with CKD with new or worsening RH in the roxadustat and DA groups were 31.4% (38 of 121) and 39.8% (51 of 128), respectively. Similar trends were apparent in subgroup analyses: patients with/without RH at baseline and with/without diabetes mellitus at baseline. In both studies, there were no differences in retinal thickness, visual acuity, presence of hard exudates or cotton wool spots, or presence of intra- and subretinal fluid between groups, at any given time point. CONCLUSION: In these studies, roxadustat, compared with DA, was not associated with an increased risk of adverse ophthalmologic events in these cohorts.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sepah YJ, Nguyen QD, Yamaguchi Y, et al. Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin. Kidney Int Rep. 2022. PMID: 35497806. doi:10.1016/j.ekir.2022.01.1045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。